Provided by Tiger Fintech (Singapore) Pte. Ltd.

Akoya Biosciences, Inc.

1.50
+0.02001.35%
Post-market: 1.570.0700+4.67%19:03 EDT
Volume:227.31K
Turnover:341.70K
Market Cap:74.36M
PE:-1.28
High:1.78
Open:1.50
Low:1.48
Close:1.48
Loading ...

BUZZ-Akoya Biosciences gains on merger deal with Quanterix

Reuters
·
10 Jan

Akoya Biosciences Shares Extend Gains, Last up 51.2% Premarket

THOMSON REUTERS
·
10 Jan

Quanterix to acquire Akoya Biosciences in an all-stock transaction

TIPRANKS
·
10 Jan

BRIEF-Quanterix To Acquire Akoya Biosciences

Reuters
·
10 Jan

Quanterix to Buy Akoya Biosciences in All-Stock Deal

MT Newswires Live
·
10 Jan

Quanterix Corp - Shareholders to Own 70% of Combined Company

THOMSON REUTERS
·
10 Jan

Quanterix Corp - Expected $40 Million Annual Cost Synergies by End of 2026

THOMSON REUTERS
·
10 Jan

Quanterix Corp - to Acquire Akoya Biosciences in All-Stock Transaction

THOMSON REUTERS
·
10 Jan

Quanterix Corp - Akoya Shareholders to Receive 0.318 Shares of Quanterix Stock per Share

THOMSON REUTERS
·
10 Jan

Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

THOMSON REUTERS
·
10 Jan

Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers

Business Wire
·
10 Jan

BRIEF-Quanterix Is Close To All-Stock Deal For Akoya Bioscience - Bloomberg News

Reuters
·
10 Jan

Quanterix Is Close to All-Stock Deal for Akoya Bioscience - Bloomberg News

THOMSON REUTERS
·
10 Jan

Akoya Biosciences Secures Exclusive License for NeraCare's Immunoprint Test

MT Newswires Live
·
10 Dec 2024

Akoya Biosciences and Neracare Enter Into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

THOMSON REUTERS
·
10 Dec 2024

Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

GlobeNewswire
·
10 Dec 2024